Riboxx Pharmaceuticals, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and Accinov, a pharmaceutical establishment for experimental drug products, announced the successful industrial GMP manufacturing, including packaging and quality control of Riboxxim, a novel and highly potent Toll-like Receptor 3 (TLR3)-ligand.

Manufacturing has been performed with the patented process Tenpora of Riboxx in full compliance with the EU GMP requirements, and with the GMP specifications of the experimental drug.

Riboxxim is a proprietary drug substance of Riboxx Pharmaceuticals. It activates the innate immune system to eliminate cancer cells as a validated approach in immuno-oncology with the historical TLR3 ligand poly(I:C) and its derivatives.

Riboxxim has been validated in multiple pre-clinical studies for immunotherapy of cancer. It displays unique physico-chemical and biological properties, as well as optimal biodisponibility with increased stability to degradation in body fluids such as human plasma. Riboxxim is stable as a drug product in liquid form for several months.

“We are proud to have reached this important milestone in the development of TLR3 ligands, with a unique, highly potent and stable drug product as a better alternative to poly(I:C) and its derivatives,” said Jacques Rohayem, chief executive officer and chief science officer, Riboxx Pharmaceuticals. Riboxxim is available for pharmaceuticals companies or universities developing clinical applications in immuno-oncology and therapeutic vaccines.”

André Dupont, president, Accinov, said, “We are proud to be the manufacturer of this innovative experimental drug. This achievement demonstrates the high flexibility of the Accinov model.”